CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry, as a full-service, non-clinical global drug development partner. Its business spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services that carry clients from target identification through non-clinical development and product release. The company divides its operations into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue reached $4.0 billion, with DSA contributing 59.8% of the top line, RMS contributing 21.1%, and Manufacturing contributing 19.1%. That concentration in DSA makes the segment the dominant economic engine.

The company’s scale is geographic as well as operational: it currently runs more than 120 sites across more than 20 countries. However, competitive position cannot be judged from scale alone. The current financials show a net margin of -6.0% and a return on equity of -7.7%, meaning the business is not generating positive accounting profitability at this snapshot. A durable competitive moat is typically associated with consistently positive, above-cost returns; those figures are absent here, so the margin/ROE profile points to a business that is still working through profitability pressures rather than extracting clear excess returns.

Financial posture

CRL carries a market capitalization of $13.8 billion and trades at a P/E of -59.4, a ratio that reflects reported losses rather than a premium or discount in the traditional valuation sense. The negative net margin of -6.0% and negative ROE of -7.7% align with that negative multiple, confirming the company has been in the red on the bottom line. With a beta of 1.38, the stock has exhibited materially higher volatility than the broader market, meaning it has historically moved about 38% more than market swings.

At the current snapshot price of $287.255, the stock sits well above its 50-day exponential moving average of $251.56, and the RSI is 63.2, approaching but still below the 70 threshold often watched for overbought conditions. That positioning suggests the recent rally has carried the price to a technically stretched level relative to its short-term trend, though RSI alone does not confirm exhaustion. The combination of negative trailing earnings, elevated beta, and a price premium to the 50-day EMA frames CRL as a valuation puzzle: the market is pricing in recovery expectations that the current income statement has not yet validated.

Strategic priorities & outlook

The company’s most recent SEC 10-K filing outlines several near-term operational priorities. First, Charles River is optimizing its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. That restructuring is aimed at reducing complexity and cost in the two largest parts of the business. Second, management is integrating Discovery Services and Safety Assessment into a single overarching DSA organization, with a combined sales force and unified leadership approach, rather than running them as separate silos. Third, the company is pursuing the objective of being the “scientific partner of choice” by delivering a comprehensive and integrated portfolio to accelerate biomedical research and therapeutic innovation.

On the growth side, the 10-K highlights an effort to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. The January 2026 acquisition of certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, supports DSA supply operations and RMS third-party sales, tightening vertical integration around research-animal sourcing. These priorities suggest the next two years will be shaped by both cost-driven consolidation and targeted expansion in biologics testing and research-model supply.

Macro & geopolitical exposure

As a Healthcare/Medical – Diagnostics & Research company, CRL is exposed to the regulatory and trade dynamics that shape non-clinical drug development. Its clients depend on FDA and other global health-regulator approvals, so shifts in regulatory timelines, GLP standards, or animal-study requirements can alter demand for safety assessment and toxicology work. The reliance on research models—especially non-human primates—also creates exposure to animal-welfare regulations, transport restrictions, and biosecurity rules that can limit supply or raise sourcing costs.

Because the company operates in over 20 countries, currency translation is a meaningful factor: a stronger U.S. dollar would reduce the reported value of overseas revenue and earnings, while a weaker dollar would do the opposite. Trade policy matters too; cross-border movement of biological samples, research animals, and specialized reagents can be disrupted by tariffs or customs restrictions. More broadly, the segment is tied to biopharma R&D budgets, which tend to expand when capital markets are receptive and contract when funding tightens, making CRL sensitive to the health of biotechnology financing conditions.

Recent developments

Recent news flow has carried a market-sentiment tilt. On August 31, 2026, defenseworld.net published a piece contrasting Charles River Laboratories with IB Acquisition (NASDAQ:IBAC). On August 24, 2026, the same outlet reported that Great Lakes Advisors LLC made a new $459,000 investment in CRL. That kind of new institutional position is a data point traders often watch for evidence of fresh capital flowing into the name. Earlier, on August 21, 2026, Zacks.com asked whether CRL’s 33.3% jump over the prior month could keep running, a headline that itself captures the post-rally momentum mindset. Separately, on August 27, 2026, Fool.com covered broader Wall Street sentiment around the Clarity Act and crypto markets; while not directly about Charles River, it sits in the same headline feed and reminds readers that CRL is also trading within a wider risk-asset environment.

Earnings behavior & post-earnings drift

CRL has a strikingly consistent earnings record over the last eight reported quarters: it beat estimates in all eight quarters, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day price move following those reports is 1.24% to the upside, classified as an upward post-earnings drift. That pattern suggests the market has generally responded favorably once the numbers are out, even if the next-day reaction has not always been directional.

Looking at the last four reports, the variability beneath the headline drift is notable. On August 5, 2026, CRL reported $3.02 versus a $2.74 estimate, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five days. On May 7, 2026, the company delivered $2.06 against $1.96, a 5.1% beat, yet the market reaction was negative, with a 2.23% drop the next day and a 12.42% decline over the next five sessions. On February 18, 2026, a $2.39 actual versus $2.33 estimate (2.6% surprise) produced a 3.95% one-day gain and a 6.05% five-day gain. On November 5, 2025, $2.43 versus $2.32, a 4.7% surprise, led to a 1.9% next-day rise and a 2.27% five-day rise. The next scheduled report is November 4, 2026, before the market opens, with a consensus EPS estimate of $2.96. The average surprise and average drift are helpful context, but the May 2026 episode shows that even a beat can be met with selling, which is why traders treat post-earnings drift as a tendency rather than a certainty.

For a deeper picture of how institutional analysts and quantitative models currently weigh these fundamentals, momentum signals, and earnings statistics, readers should examine the full institutional verdict on the ticker.